Leukemia Clinical Trials in Boston

Showing 1221-1240 of 1,445 trials

Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit

NCT01527838

This trial is a prospective, open-label, single-arm trial of the safety of a single FT1050-treated CB unit for hematopoietic reconstitution after a reduced-intensity conditioning regimen for hematologic malignancies. A maximum of 40 eligible adult subjects will be enrolled and treated in the trial at approximately 2-4 centers within the U.S.

Non-Hodgkin's Lymphoma (NHL)Hodgkin's DiseaseChronic Lymphocytic Leukemia (CLL)+2 more

Fate Therapeutics10 participantsStarted Jan 2012

Boston, Massachusetts, United States • Boston, Massachusetts, United States • Columbus, Ohio, United States

COMPLETEDPhase 1< 1 mile

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

NCT01209195

This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial of MM-121 in combination with paclitaxel using a "3+3" design.

Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,Primary Peritoneal Cancer or Endometrial CancerLocally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer

Merrimack Pharmaceuticals41 participantsStarted Oct 2010

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Bakersfield, California, United States +2 more locations

COMPLETEDPhase 1/2< 1 mile

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

NCT00994123

A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).

Carcinoma, Non-Small-Cell Lung

Merrimack Pharmaceuticals162 participantsStarted Feb 2010

Birmingham, Alabama, United States • Tucson, Arizona, United States • Loma Linda, California, United States +35 more locations

Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Leukemia Trials in Other Cities

Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer

Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa

Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL

Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL

Evaluation of EverOn™ System in Medical / Surgical Ward

Seasonal Allergic Rhinitis In Pediatric Subjects

Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes

Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC

BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

Metronomic Chemotherapy in Advanced Gastric Cancer

Other Conditions in Boston